Eliquis to face generic competition in late 2026? Bristol Myers Squibb (BMS) and Pfizer’s oral blood thinner – Eliquis® (Apixaban) was approved in the United
Generics for Otezla® to be out in the United States in February 2028 Amgen’s oral phosphodiesterase-4 (PDE-4) inhibitor – Otezla® (Apremilast) is approved in the
Inflation Reduction Act: Patients sigh relief but confusion for biosimilar manufacturers The Inflation Reduction Act of 2022 (IRA) was signed into law in the United
First generic of Vyvanse® launched in the United States Vyvanse® (Lisdexamfetamine dimesylate), a schedule C-II controlled substance, was approved by the U.S. Food and Drug Administration
Stelara® Biosimilars: Relief for plaque psoriasis patients Johnson & Johnson’s (J&J) plaque psoriasis blockbuster drug, Stelara® (Ustekinumab), gained its first approval from U.S. FDA in September 2009.
